Observational, Post-authorization, Cross-sectional Study to Evaluate the Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
The main aim of this study is to compare the prognostic value of R-IPI at diagnosis and
relapse, relating it with the obtained response after second line
Observational
Observational Model: Case-Only, Time Perspective: Cross-Sectional
R-IPI Index
Data will be recorded from diagnosis to second line response, an expected average of 7 months
Average of 7 months
No
Carlos Panizo, PhD
Study Chair
Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea
Spain: Spanish Agency of Medicines
PRO-R-IPI
NCT01369784
February 2009
March 2011
Name | Location |
---|